HB-0036

N/A

Report date: 2023/12/08 14:52:02

Base Information

Drug NameHB-0036
Drug Alias NameHB-0036
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-T cell immunoglobulin and ITIM domains
TargetsProgrammed death-ligand 1T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHuaBo Biopharm Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A